Chaperonin (HSP60) and annexin-2 are candidate biomarkers for non-small cell lung carcinoma

Abstract

Background:Lung cancer is responsible of 12.4% and 17.6% of all newly diagnosed cancer cases and mortality due to cancer, respectively, and 5-year survival rate despite all improved treatment options is 15%. This survival rate reaches 66% in the Stage 1 and surgically treated patients. Early diagnosis which could not be definitely and commonly achieved yet is extremely critical in obtaining high survival rate in this disease. For this reason; proteomic differences were evaluated using matrix assisted laser desorption ionization (MALDI) mass spectrometry in the subgroups of lung adenocarcinoma and squamous cell carcinoma.Methods:Fresh tissue samples of 36 malignant cases involving 83.3% (n = 30) men and 16.7% (n = 6) women patients were distributed into 2 groups as early and end stage lung cancer and each group were composed of subgroups including 18 squamous cell carcinoma (9 early stage cases, 9 end stage cases) and 18 adenocarcinoma cases (9 early stage cases, 9 end stage cases). The fresh tissues obtained from the tumoral and matched normal sites after surgical intervention. The differences in protein expression levels were determined by comparing proteomic changes in each patient.Results:In the subgroups of advanced stage adenocarcinoma; tumoral tissue revealed differences in expression of 2 proteins compared with normal parenchymal tissue. Of those; difference in protein expression in heat shock protein 60 (HSP60) was found statistically significant (P = 0.0001). Subgroups of early and advanced stage squamos cell carcinoma have differed in certain 20 protein expression of normal tissue and diseased squamos cell carcinoma. Of those, increased protein expression level of only annexin-2 protein was found statistically significant (P = 0.002). No significant difference was detected in early and advanced stage protein expressions of the tumoral tissues in the subgroups of adenocarcinoma and squamous cell carcinoma.Conclusions:We conclude that with respect to early diagnosis of lung cancer that HSP60 and annexin-2 proteins are the important biomarkers in the subgroups of adenocarcinoma and squamous cell carcinoma. We also consider that these 2 proteins are molecules which may provide critical contribution in evaluation of prognosis, metastatic potential, response to treatment, and in establishment of differential diagnosis between adenocarcinoma and squamous cell carcinoma.

Retrospective Proteomic Screening of 100 Breast Cancer Tissues

“…In particular, the high expression of HSPB1 is associated with poor prognosis in several carcinomas and osteosarcomas [77], while CH60, with Annexin-2, represents a potential biomarker for subtypes of lung carcinoma [78]. In our tumors we detected 7 isoforms of HSBP1, 4 of them were ubiquitous and 3 sporadic The 4 ubiquitous isoforms showed a modest average increase versus the normal tissues.…”

Clinical Application of Mass Spectrometry‐Based Proteomics in Lung Cancer Early Diagnosis

“…Genesis, progression, recurrence, and metastasis of squamous cell carcinoma. [80,55,72,20,68] Complement factor Essential role in the activation of the innate immunity. Reflects progression of malignancy, including lung cancer.…”

Heat shock protein 60 is a disease-associated sialoglycoprotein in human non-small cell lung cancer

“…HSP60, the mammalian molecular chaperone, has a crucial role in protein homeostasis via regulating protein folding and assembly (Okamoto et al, 2017). The level of HSP60 was found to be increased in ovarian cancer, androgen-independent locally advanced prostate cancer and lung cancer, in which its presence was detected intracellularly, pericellularly and also in circulation (Castilla et al, 2010;Bodzek et al, 2014;Agababaoglu et al, 2017). Cytosolic HSP60 was shown to have a prognostic association with cervical cancer and colorectal cancer (Cappello et al, 2009;Hwang et al, 2009).…”

“…Our findings clearly indicated the involvement of sialylated mHSP60 in the migration of both the NSCLC cell lines, as this process could be inhibited in the presence of HSP60-antibody. In this context, it can be mentioned that annexin-II and HSP60 have been reported as the important future biomarkers for NSCLC, which may have a decisive role in assessment of metastatic potential, response to cure and in the establishment of differential diagnosis for adenocarcinoma and squamous cell carcinoma patients (Agababaoglu et al, 2017).…”